Fritextsökning
Artiklar per år
Innehållstyper
-
Ny forskarskola ska skapa spetskompetens i ATMP
Det kommer att behövas 500 personer med spetskompetens inom avancerade terapiläkemedel inom några år. För att lyckas med det startar nu fem lärosäten tillsammans en forskarskola för doktorander, med bas i Lund.
-
ALS – When the body has given up, but the brain persists
The nerve disease ALS gradually deprives the patient of control over the muscles and, eventually, also of speech. The eyes continue to function, though, and with the help of, among other things, a Swedish-developed invention, communication with the outside world can continue. “It’s their window to the world,” says ALS researcher Caroline Ingre.
-
“Photon counting in computed tomography is the holy grail”
Erik Fredenberg, a researcher in physics at KTH and GE, is working to implement photon-counting CT in clinics. To shorten lead times and reduce the radiation dose in patients, he is setting out to develop a framework for virtual clinical trials for the technology.
-
New study: Post-Covid symptoms are common even after mild Covid-19
According to researchers at the University of Gothenburg, loss of smell and taste, shortness of breath and chest symptoms are the most common complaints after a mild Covid infection.
-
He is zooming in on topical preparations
According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new GMP facility.
-
Swedish breakthrough in Alzheimer’s: “We can finally present great data”
Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm.
-
Neanderthal genes and Nobel Prize in a popular lecture at Bioscience
An inherited gene variant from our ”evolutionary cousins” – the extinct Neanderthals – may affect how our bodies break down certain drugs. “It’s only a matter of time before we actively start screening for it,” said KI researcher Hugo Zeberg when describing the study at Bioscience 2022.
-
"Are we doing business the wrong way around in the Life Science Sector?"
For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which were great for that time but now we realise that these drugs were in fact only tested in white men and certainly not for patients who are older who are taking a number of medications.
-
A green nursery for biotech rooted in the Scanian soil
Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders, Johan Evenäs and Martina Kvist Reimer.
-
Gesyntas beslut: Ska utveckla läkemedel mot endometrios
Gesynta Pharma har beslutat att gå vidare med utvecklingen av en icke-hormonell behandling av endometrios, en smärtsam sjukdom som drabbar bortåt var tionde kvinna i fertil ålder.
-
Alert from the Swedish Medicines Agency: Many complications with gastric balloons
According to the Swedish Medicines Agency, an increasing number of serious complications are being reported in procedures with gastric balloons as a method for weight loss. The authority fears significant shortcomings in the information to patients both before and after the procedure.
-
“We need to build flexible operating theatres”
Flexible operating theatres, micro-sensors on surgeons to monitor their well-being and 3D images projected onto organs to be operated on. These are a few ideas that three specialist surgeons are suggesting for the operating theatre of the future.
-
Cytel Inc acquires the SDS Group
The multinational statistical software developer and contract research organization Cytel Inc, headquartered in Massachusetts, USA, acquires the Swedish consulting company SDS Life Science.
-
“We aim to be a start-up company with an academic spirit”
Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working on developing drugs for both conditions.
-
The TFS family is growing
TFS HealthScience is a European based CRO company with broad expertise and experiences in the biotech and pharmaceutical sector. The company is growing and the TFS family welcomes new members.
-
“We need to keep investing in research and innovation”
Jenni Nordborg has worked for just over four years to highlight life science in Sweden. Her mandate as national coordinator ends in December 2022. ““Life sciences has been a long-term priority of governments since many years and I have no doubt that the ambitions will be strong going forward”, says Jenni Nordborg.
-
Regsmart startar samarbete för att erbjuda klinisk utveckling
Under september månad startade konsultföretaget Regsmart ett samarbete med Matthias Rother och Rolf Karlsten för att i fortsättningen även kunna erbjuda kliniska utvecklingsplaner för läkemedel och medicinteknik till kunder.
-
Business Sweden’s new team is rolling out the blue-yellow carpet
According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sweden. “It’s a perfect storm, a beneficent, perfect storm,” says Programme Manager Britta Stenson.
-
FOKUS Patient turns international
FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward to the outcome of the pilot to hopefully then understand if “in house” analyses actually will add value.
-
Life Science-podden: The perfect moment for an IPO
When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.
-
Genes from Neanderthals can affect the correct drug dosage
A fifth of all Europeans carry gene variants inherited from Neanderthals, which cause certain drugs to break down more slowly. This may have implications for the drug doses they should take.